What are the commercial prospects for antibacterial treatments? Visiongain's report shows you potential revenue values to 2022. Find data, forecasts and discussions.

Discover sales predictions at world market, therapeutic class, product and national levels to 2022. Our report gives you business research, analysis and opinion for the treatment of bacterial infections.

How will 20 leading products - including Levaquin, Zyvox, Avelox, Augmentin, Zosyn, Merrem, Cubicin, Primaxin and Cravit - perform to 2022? You can find potential revenues, with discussions.

Also, receive forecast values for cephalosporin, penicillin, fluoroquinolone, macrolide and carbapenem submarkets. We analyse other agents too. See possible sales trends for antibiotics from 2012.

This study discusses Pfizer, Merck, GSK, Cubist, Abbott, Bayer and other pharmaceutical companies. Receive analyses for anti-infective agents in human healthcare, including hospital-acquired infections.

What does the future hold? With its R&D pipeline, the antimicrobial drug industry has potential for improved treatment of bacterial diseases. Bacteria still pose a great threat, with antibiotic resistance staying a challenge in clinical practice.

Visiongain's report provides data, analysis and opinion aiming to benefit your research, calculations, meetings and presentations. You can find answers now in our work.

Revenue forecasts, market shares, developmental trends, discussions and interviews

In our report, you find revenue forecasting, growth rates, market shares, qualitative analyses (incl. SWOT and STEP), views and R&D news. You receive 149 tables and charts and two research interviews.

Advantages of Antibacterial Drugs: World Market Prospects 2012-2022 for your work

In particular, our study gives you the following knowledge and benefits:
• Find revenue predictions to 2022 for the overall world antibacterial drug market and submarkets, seeing revenue growth
• Discover revenue forecasts to 2022 for 20 leading products, assessing commercial potential
• See revenue forecasts to 2022 for leading national markets - US, Japan, China, India, Brazil, France, Italy, Germany, UK and Spain
• Assess leading companies, discovering their activities and prospects
• Review R&D for treating bacterial diseases, seeing pipeline trends
• Investigate competition and opportunities influencing the sector and its sales
• Find out what will stimulate and restrain the industry and market
• View opinions from our survey, discovering interviews with industrial experts.

There, you find a distinctive mix of quantitative and qualitative work with independent predictions. We tackle crucial questions on antibacterials, helping you to stay ahead.

Gain business research, data and analysis for antibacterial agents

Our study is for everybody needing industry and market analyses for bacterial anti-infective medicine. Find data, trends and answers. Avoid missing out - please order our report now.

1. Executive Summary
1.1 Antibacterial Drugs: World Market Review
1.2 Chapter Breakdown
1.3 Research and Analysis Methods

2. An Introduction to Bacteria, Bacterial Infections and Antibacterial Drugs
2.1 Bacteria and Bacterial Infections
2.1.1 Bacteria
2.1.2 Clinically Important Bacteria
2.1.3 Bacterial Infections
2.1.3.1 Bacteria's Infectious Activity
2.2 Antibacterial Drugs
2.2.1 A History of Antibacterial Drugs
2.2.1.1 Penicillin
2.2.1.2 Other Key Steps in the History of Antibacterial Drugs
2.2.2 Mechanisms of Action for Antibacterial Drugs

3. The Antibacterial Drugs Market 2012-2022
3.1 The Antibacterial Drugs Market 2010-2011
3.2 The Antibacterial Drugs Market: Overall Revenue Forecast 2012-2022
3.2.1 Generic Competition
3.2.2 Prescribing Antibacterial Drugs
3.2.3 Bacterial Resistance
3.2.4 R&D Pipeline Will Restrain Growth?
3.3 Cephalosporins Submarket 2010-2011
3.3.1 Cephalosporins Submarket: Revenue Forecast 2012-2022
3.4 Penicillin Submarket 2010-2011
3.4.1 Penicillins Submarket: Revenue Forecast 2012-2022
3.5 Fluoroquinolone Submarket 2010-2011
3.5.1 Fluoroquinolones are Linked with Side Effects
3.5.2 Fluoroquinolone Pipeline 2011
3.5.3 Fluoroquinolone Submarket: Revenue Forecast 2012-2022
3.6 Macrolide Submarket 2010-2011
3.6.1 Dificid: A New Macrolide
3.6.2 Macrolide Submarket: Revenue Forecast 2012-2022
3.7 Carbapenems Submarket 2010-2011
3.7.1 Doribax (Doripenem, Ortho-McNeil/Shionogi)
3.7.2 Carbapenems Submarket: Revenue Forecast 2012-2022
3.8 Other Antibacterial Drugs Submarket 2010-2011
3.8.1 Vibativ
3.8.2 Other Antibacterial Drugs Submarket: Revenue Forecast 2012-2022

4. Leading Antibacterial Drugs: Market Prospects to 2022
4.1 Leading Antibacterial Drugs Overview
4.2 Levaquin
4.2.1 Levaquin: Revenue Forecast 2012-2022
4.3 Zyvox
4.3.1 Zyvox: Revenue Forecast 2012-2022
4.4 Avelox
4.4.1 Avelox: Revenue Forecast 2012-2022
4.5 Augmentin
4.5.1 Augmentin: Revenue Forecast 2012-2022
4.6 Zosyn
4.6.1 Zosyn: Revenue Forecast 2012-2022
4.7 Merrem
4.7.1 Merrem: Revenue Forecast 2012-2022
4.8 Cubicin
4.8.1 Cubicin: US Revenue Forecast 2012-2022
4.9 Primaxin
4.9.1 Primaxin: Revenue Forecast 2012-2022
4.10 Biaxin
4.11 Cravit
4.11.1 Cravit: Revenue Forecast 2012-2022
4.12 Zithromax
4.13 Invanz
4.13.1 Invanz: Revenue Forecast 2012-2022
4.14 Cipro
4.15 Tygacil
4.15.1 Tygacil: Revenue Forecast 2012-2022
4.16 Rocephin
4.16.1 Rocephin: Revenue Forecast 2012-2022
4.17 Zinnat
4.18 Flomox
4.19 Unasyn
4.20 Dalacin C
4.21 Meiact

5. Leading National Antibacterial Drug Markets 2012-2022
5.1 Leading National Markets 2010-2011
5.2 Leading National Markets: Revenue Forecasts 2012-2022
5.3 The European Market: Revenue Forecasts 2012-2022
5.4 The US: Revenues 2012-2022
5.5 China: Revenues 2012-2022
5.6 Japan: Revenues 2012-2022
5.7 India: Revenues 2012-2022
5.8 Brazil: Revenues 2012-2022

6. Antibacterial Drugs R&D Pipeline in 2011
6.1 Zinforo (Ceftaroline, AstraZeneca/Forest Laboratories)
6.2 Ceftobiprole (Basilea Pharmaceutica)
6.3 Restanza (Cethromycin, Advanced Life Sciences): Any Future Development?
6.4 Dalbavancin (Durata Therapeutics)
6.5 Nuvocid (Oritavancin, The Medicines Company)
6.6 TR-701 (Tedizolid, Trius Therapeutics)
6.7 CAZ104 (Ceftazidime/Avibactam, AstraZeneca/Forest Laboratories)
6.7.1 CEF104 (Ceftaroline/Avibactam, AstraZeneca/Forest Laboratories)
6.8 CXA-201 (Cubist)
6.9 NKTR-061 (Amikacin Inhalation, Bayer/Nektar Therapeutics)
6.10 Ramoplanin (Nanotherapeutics)
6.11 Radezolid (Rib-X Pharmaceuticals)

7. Antibacterial Drugs: Industry Trends 2012-2022
7.1 Strengths and Weaknesses in the Antibacterial Drugs Market 2011
7.2 Opportunities and Threats in the Antibacterial Drugs Market 2012-2022
7.3 Late-Stage Pipeline Therapies
7.3.1 Governmental Incentives
7.4 New Strategies
7.4.1. Monoclonal Antibodies
7.4.2 Inhaled Antibiotics for Hospital-Acquired Pneumonia
7.5 Bacterial Resistance: An Opportunity and a Threat
7.5.1 Emerging Resistance
7.5.2 Restricting Drug Use
7.6 The Challenge of Non-Inferiority Trials
7.7 Improved Regulatory Guidance
7.8 Lifecycle Management
7.9 Hospital-Acquired Infections
7.9.1 Treating Hospital-Acquired Infections
7.9.2 Preventing Hospital-Acquired Infections
7.9.3 Hospital Hygiene
7.9.4 Tracking Infections
7.9.5 Advances in Hospital Equipment
7.9.5.1 Copper Kills Bacteria

8. Research Interviews8.1 Professor Malcolm Page, Head of Biology, Basilea Pharmaceutica
8.1 Professor Malcolm Page, Head of Biology, Basilea Pharmaceutica
8.1.1 Basilea Pharmaceutica
8.1.2 Antibacterial Research This Decade
8.1.3 Challenges in Developing Treatments for Gram-Negative Bacteria
8.1.4 Overcoming Drug Resistance
8.1.5 New Targets for Antibacterial Drug Development
8.2 Dr Michael Rudolf, CSO, Kenta Biotech
8.2.1 Kenta Biotech
8.2.2 Monoclonal Antibodies for Bacterial Infections
8.2.3 Challenges in Developing Treatments for Gram-Negative Bacteria
8.2.4 Unmet Needs in the Antibacterial Drugs Market

9. Conclusions from Our Study
9.1 Antibacterial Drugs Market 2012-2022
9.1.1 Leading Product Performance 2012-2022
9.2 The R&D Pipeline: Outlook for the Future
9.3 Bacterial Resistance: a Rising Challenge

Other Content
Glossary: Clinical Bacteriology

List of Tables

Table 1.1 Currency Exchange Rates
Table 1.2 Common Abbreviations Used in this Report
Table 2.1 Common Causes of Hospital-Acquired Infections Worldwide, 2011
Table 2.2 Examples of Clinically-Important Bacteria, 2011
Table 2.3 Mechanism of Action for Leading Antibacterial Drug Classes
Table 3.1 Antibacterial Drugs Market by Class, 2010
Table 3.2 Antibacterial Drugs Market: Overall Market and Revenue Forecasts by Class, 2010-2022
Table 3.3 Antibacterial Drugs Market: Drivers and Restraints, 2012-2022
Table 3.4 Antibacterial Drugs: Submarket Shares, 2010-2022
Table 3.5 Cephalosporins Submarket: Drug Revenues, 2010
Table 3.6 Cephalosporins Submarket: Revenue Forecast, 2010-2022
Table 3.7 Cephalosporins Submarket: Drivers and Restraints, 2012-2022
Table 3.8 Penicillins Submarket: Drug Revenues, 2010
Table 3.9 Penicillins Submarket: Drivers and Restraints, 2012-2022
Table 3.10 Penicillins Submarket: Revenue Forecast, 2010-2022
Table 3.11 Fluoroquinolones Submarket: Drug Revenues, 2010
Table 3.12 Penicillins Submarket: Drivers and Restraints, 2012-2022
Table 3.13 Fluoroquinolones Submarket: Revenue Forecast, 2010-2022
Table 3.14 Macrolides Submarket: Drug Revenues, 2010
Table 3.15 Macrolides Submarket: Drivers and Restraints, 2012-2022
Table 3.16 Macrolides Submarket: Revenue Forecast, 2010-2022
Table 3.17 Carbapenems Submarket: Drug Revenues, 2010
Table 3.18 Carbapenems Submarket: Drivers and Restraints, 2012-2022
Table 3.19 Carbapenems Submarket: Revenue Forecast, 2010-2022
Table 3.20 Other Antibacterial Drugs Submarket: Drug Revenues, 2010
Table 3.21 Other Antibacterial Drugs Submarket: Revenue Forecast, 2010-2022
Table 4.1 Top 20 Antibacterial Drugs, 2010
Table 4.2 2010 Top 20 Antibacterial Drugs: Revenue Forecast, 2010-2022
Table 4.3 Levaquin Key Facts, 2011
Table 4.4 Levaquin: Revenue Forecast, 2010-2022
Table 4.5 Zyvox Key Facts, 2011
Table 4.6 Zyvox: Nine-Month Revenue, 2010-2011
Table 4.7 Zyvox: Revenue Forecast, 2010-2022
Table 4.8 Avelox Key Facts, 2011
Table 4.9 Avelox: Six-Month Revenue by Company, 2010-2011
Table 4.10 Avelox: Revenue Forecast, 2010-2022
Table 4.11 Augmentin Key Facts, 2011
Table 4.12 Augmentin: Revenue Forecast, 2010-2022
Table 4.13 Zosyn Key Facts, 2011
Table 4.14 Zosyn: Nine-Month Revenue, 2010-2011
Table 4.15 Zosyn: Revenue Forecast, 2010-2022
Table 4.16 Merrem Key Facts, 2011
Table 4.17 Merrem: Nine-Month Revenue, 2010-2011
Table 4.18 Merrem: Revenue Forecast, 2010-2022
Table 4.19 Cubicin Key Facts, 2011
Table 4.20 Cubicin: Nine-Month Revenue, 2010-2011
Table 4.21 Cubicin: Revenue Forecast, 2010-2022
Table 4.22 Primaxin Key Facts, 2011
Table 4.23 Primaxin: Revenue Forecast, 2010-2022
Table 4.24 Biaxin Key Facts, 2011
Table 4.25 Biaxin: Revenue Forecast, 2010-2022
Table 4.26 Cravit Key Facts, 2011
Table 4.27 Cravit: Revenue, Fiscal Years 2006-2011
Table 4.28 Cravit: Revenue Forecast, 2010-2022
Table 4.29 Zithromax Key Facts, 2011
Table 4.30 Zithromax: Nine-Month Revenue, 2010-2011
Table 4.31 Zithromax: Revenue Forecast, 2010-2022
Table 4.32 Invanz Key Facts, 2011
Table 4.33 Invanz: Six-Month Revenue, 2010-2011
Table 4.34 Invanz: Revenue Forecast, 2010-2022
Table 4.35 Cipro Key Facts, 2011
Table 4.36 Cipro: Revenue Forecast, 2010-2022
Table 4.37 Tygacil Key Facts, 2011
Table 4.38 Tygacil: Nine-Month Revenue, 2010-2011
Table 4.39 Tygacil: Revenue Forecast, 2010-2022
Table 4.40 Rocephin Key Facts, 2011
Table 4.41 Rocephin: Revenue Forecast, 2010-2022
Table 4.42 Zinnat Key Facts, 2011
Table 4.43 Zinnat: Revenue Forecast, 2010-2022
Table 4.44 Flomox Key Facts, 2011
Table 4.45 Flomox: Revenue Forecast, 2010-2022
Table 4.46 Unasyn Key Facts, 2011
Table 4.47 Unasyn: Revenue Forecast, 2010-2022
Table 4.48 Dalacin C Key Facts, 2011
Table 4.49 Dalacin C: Revenue Forecast, 2010-2022
Table 4.50 Meiact Key Facts, 2011
Table 4.51 Meiact: Revenue Forecast, 2010-2022
Table 5.1 Antibacterial Drugs Market by Region, 2010
Table 5.2 Antibacterial Drugs Market: Revenue Forecasts by Region, 2010-2022
Table 5.3 European Antibacterial Drugs Market by Country, 2010
Table 5.4 European Antibacterial Drugs Market: Revenue Forecasts by Country, 2010-2022
Table 6.1 Selected Antibacterial Pipeline Candidates Discussed
Table 6.2 Selected Antibacterial Pipeline Candidates Not Discussed
Table 7.1 Antibacterial Drugs Market: Strength and Weaknesses, 2011
Table 7.2 Antibacterial Drugs Market: Opportunities and Threats, 2012-2022
Table 7.3 Selected Inhaled Antibiotics in Development, 2011
Table 9.1 Antibacterial Drugs Market: Revenues by Class, 2010, 2016 and 2022
Table 9.2 Fate of the 2010 Top 20 Antibacterial Drugs: Combined Revenues, 2010, 2016 and 2022

List of Figures

Figure 2.1 Milestones in the History of Antibacterial Agents, 1940-2011
Figure 3.1 Antibacterial Drugs: Market Shares by Class, 2010
Figure 3.2 Antibacterial Drugs Market: Overall Market and Revenue Forecasts by Class, 2010-2022
Figure 3.3 Antibacterial Drugs: Market Shares by Class, 2016
Figure 3.4 Antibacterial Drugs: Market Shares by Class, 2022
Figure 3.5 Cephalosporins Submarket: Market Shares, 2010
Figure 3.6 Cephalosporins Submarket: Revenue Forecast, 2010-2022
Figure 3.7 Penicillins Submarket: Market Shares, 2010
Figure 3.8 Penicillins Submarket: Revenue Forecast, 2010-2022
Figure 3.9 Fluoroquinolones Submarket: Market Shares, 2010
Figure 3.10 Fluoroquinolones Submarket: Revenue Forecast, 2010-2022
Figure 3.11 Macrolides Submarket: Market Shares, 2010
Figure 3.12 Macrolides Submarket: Revenue Forecast, 2010-2022
Figure 3.13 Carbapenems Submarket: Market Shares, 2010
Figure 3.14 Carbapenems Submarket: Revenue Forecast, 2010-2022
Figure 3.15 Other Antibacterial Drugs Submarket: Market Shares, 2010
Figure 3.16 Other Antibacterial Drugs Submarket: Revenue Forecast, 2010-2022
Figure 4.1 Top 20 Antibacterial Drugs, 2010
Figure 4.2 2010 Top 20 Antibacterial Drugs: Grouped Revenue Forecast, 2010-2022
Figure 4.3 Levaquin: Revenue Forecast, 2010-2022
Figure 4.4 Zyvox: Nine-Month Revenue, 2010-2011
Figure 4.5 Zyvox: Revenue Forecast, 2010-2022
Figure 4.6 Avelox: Six-Month Revenue by Company, 2010-2011
Figure 4.7 Avelox: Revenue Forecast, 2010-2022
Figure 4.8 Augmentin: Revenue Forecast, 2010-2022
Figure 4.9 Zosyn: Nine-Month Revenue, 2010-2011
Figure 4.10 Zosyn: Revenue Forecast, 2010-2022
Figure 4.11 Merrem: Nine-Month Revenue, 2010-2011
Figure 4.12 Merrem: Revenue Forecast, 2010-2022
Figure 4.13 Cubicin: Nine-Month Revenue, 2010-2011
Figure 4.14 Cubicin: Revenue Forecast, 2010-2022
Figure 4.15 Primaxin: Revenue Forecast, 2010-2022
Figure 4.16 Biaxin: Revenue Forecast, 2010-2022
Figure 4.17 Cravit: Revenue, Fiscal Years 2006-2011
Figure 4.18 Cravit: Revenue Forecast, 2010-2022
Figure 4.19 Zithromax: Nine-Month Revenue, 2010-2011
Figure 4.20 Zithromax: Revenue Forecast, 2010-2022
Figure 4.21 Invanz: Six-Month Revenue, 2010-2011
Figure 4.22 Invanz: Revenue Forecast, 2010-2022
Figure 4.23 Cipro: Revenue Forecast, 2010-2022
Figure 4.24 Tygacil: Nine-Month Revenue, 2010-2011
Figure 4.25 Tygacil: Revenue Forecast, 2010-2022
Figure 4.26 Rocephin: Revenue Forecast, 2010-2022
Figure 4.27 Zinnat: Revenue Forecast, 2010-2022
Figure 4.28 Flomox: Revenue Forecast, 2010-2022
Figure 4.29 Unasyn: Revenue Forecast, 2010-2022
Figure 4.30 Dalacin C: Revenue Forecast, 2010-2022
Figure 4.31 Meiact: Revenue Forecast, 2010-2022
Figure 5.1 Antibacterial Drugs Market Shares by Region, 2010
Figure 5.2 Antibacterial Drugs Market Shares by Region, 2016
Figure 5.3 Antibacterial Drugs Market Shares by Region, 2022
Figure 5.4 European Antibacterial Drugs Market Shares by Country, 2010
Figure 5.5 European Antibacterial Drugs Market: Revenue Forecasts by Country, 2010-2022
Figure 5.6 US Antibacterial Drugs Market: Revenue Forecast, 2010-2022
Figure 5.7 Chinese Antibacterial Drugs Market: Revenue Forecast, 2010-2022
Figure 5.8 Japanese Antibacterial Drugs Market: Revenue Forecast, 2010-2022
Figure 5.9 Indian Antibacterial Drugs Market: Revenue Forecast, 2010-2022
Figure 5.10 Brazilian Antibacterial Drugs Market: Revenue Forecast, 2010-2022
Figure 7.1 Non-Inferiority Trials and Biocreep: A Worst Case Scenario
Figure 9.1 Antibacterial Drugs Market: Revenues by Class, 2010, 2016 and 2022
Figure 9.2 Fate of the 2010 Top 20 Antibacterial Drugs: Revenues, 2010, 2016 and 2022

Companies Menstion

Abbott Laboratories
Acino
Adimab
Advanced Life Sciences
Agência Nacional de Vigilância Sanitária (Anvisa) [Brazil]
Aisling Capital
Alliance for the Prudent Use of Antibacterials (APUA) [US]
Alopexx Pharmaceuticals
Andrx (now part of Watson Pharmaceuticals)
APP Pharmaceuticals (a subsidiary of Fresenius Kabi)
Arsanis
Astellas Pharma
AstraZeneca
Aurobindo Pharma
Barr Pharmaceuticals (now part of Teva)
Basilea Pharmaceutica
Bayer
Bioquell
C&O Pharmaceutical Technology (Holdings)
Calixa Therapeutics (now part of Cubist Pharmaceuticals)
Canaan Partners
Cempra
Centers for Disease Control and Prevention (CDC) [US]
Centers for Medicare and Medicaid Services (CMS) [US]
Cipla
Copper Development Association [US]
Cornerstone Therapeutics
Cubist Pharmaceuticals
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dr. Reddy's Laboratories
Duke University [US]
Durata Therapeutics
Eli Lilly
EMA Committee for Medicinal Products for Human Use (CHMP)
European Medicines Agency (EMA)
FDA Anti-Infective Drugs Advisory Committee (AIDAC) [US]
Food and Drug Administration (FDA) [US]
Forest Laboratories
Fresenius Kabi Pharmaceuticals
Furiex Pharmaceuticals
Future Path Medical
Gilead Sciences
Glenmark Generics
GSK
Harvard Medical School
Healthcare Infection Control Practices Advisory Committee (HICPAC) [US]
Hikma Farmaceutica
Hospira
Innocell
Insmed
Itochu Chemical Frontier
J&J
Janssen Pharmaceutica (a subsidiary of J&J)
Japan Patent Office (JPO)
KaloBios Pharmaceuticals
Kenta Biotech
King's College London
Lederle Laboratories (acquired by Wyeth, now part of Pfizer)
Lupin Pharmaceuticals
Medicines and Healthcare products Regulatory Agency (MHRA) [UK]
Meiji Seika Kaisha
Merck & Co.
Michigan State University
Ministry of Health and Family Welfare [India]
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Mpex Pharmaceuticals
Mylan
Nanotherapeutics
National Health Service (NHS) [UK]
Nektar Therapeutics
New Leaf Venture Partners
Novartis
Novexel
Optimer Pharmaceuticals
Orchid Chemicals and Pharmaceuticals
Ortho-McNeil Pharmaceuticals (a subsidiary of J&J)
Oscient Pharmaceuticals
Paratek Pharmaceuticals
Parke-Davis (now part of Pfizer)
Peking University
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA) [US]
Pharmacia (now part of Pfizer)
Pliva (now part of Teva)
RaQualia Pharma
Rib-X Pharmaceuticals
Roche
Sandoz
Sanofi
Sanofi Pasteur (part of Sanofi)
Sawai Pharmaceutical
Schering-Plough (now part of Merck & Co)
Shionogi
St Thomas' Hospital
Strides Arcolab
Sumitomo Pharmaceuticals (now part of Dainippon Sumitomo)
Takeda Pharmaceutical Company
TAP Holdings
Targanta Therapeutics (now part of The Medicines Company)
Teva Pharmaceuticals
The Medicines Company
Theravance
Trius Therapeutics
University of Birmingham [UK]
University of Pennsylvania
US Department of Defense
Vicuron Pharmaceuticals (now part of Durata Therapeutics)
Watson Pharmaceuticals
Wockhardt
World Health Organization (WHO)
Wyeth (now part of Pfizer)